US launches Section 301 probe into Germany over drug pricing
- On Thursday, the United States launched a Section 301 investigation into Germany over what it called "persistent underpayment for innovative pharmaceutical products," setting the stage for possible new tariffs.
- President Trump's administration alleges German pricing policies restrict commerce and force Americans to shoulder a "disproportionate share of global pharmaceutical research and development" costs. Germany is fast-tracking legislation to reduce drug spending.
- Stephen Ubl, president of the Pharmaceutical Research and Manufacturers of America, said his organization "appreciates the administration's commitment to challenging unfair practices abroad" and supports using Section 301 to achieve this goal.
- Trade Representative Jamieson Greer suggested the dispute could be resolved through negotiations, pointing to a US-UK deal from earlier this year as a potential model. The White House and German Embassy did not immediately respond.
- Trump has increasingly used trade probes to impose duties after the Supreme Court struck down many sweeping tariffs in February. The administration recently proposed up to 12.5 percent tariffs on dozens of economies under similar investigations.
49 Articles
49 Articles
US Launches Trade Probe Accusing Germany of Making Medicine 'Too Cheap' As Trump Pushes Global Prices Higher
Washington has opened a Section 301 trade investigation into Germany over what it calls 'persistent underpayment' for innovative medicines, a move that could end in tariffs on German pharmaceutical exports. US Trade Representative Jamieson Greer announced the probe on 18 June 2026, arguing that low German drug prices push American patients into funding a disproportionate share of global research costs. The case is the first time the Trump admini…
Donald Trump believes that the health systems in the Old Continent, which regulate the costs of drugs, are responsible for the high prices charged by laboratories across the Atlantic.
New US trade offensive against one of its partners. Washington launched an investigation on Friday, 19 June, to determine whether Germany is paying the fair price for US medicines sold in its territory. This procedure could involve retaliatory measures in Berlin, in particular new taxes on German exports.
The Epoch Times
Blue Water Healthy LivingUS Launches Trade Investigation Into Germany Over Drug Pricing
The United States has launched a trade investigation into a German plan to lower its spending on pharmaceutical products, U.S. Trade Representative Jamieson Greer said on Thursday. The United States claims that there is evidence that “Germany implements unfair pricing policies and practices with regard to innovative pharmaceutical products,” according to the Office of the Trade Representative. It added that there is also evidence “that reduced…
The United States has opened an investigation into Germany that could lead to new import tariffs. The German government is working on reforming the healthcare insurance system to save costs, including by reducing reimbursements for pharmaceutical manufacturers. According to the Trump administration, this amounts to underpayment, and an investigation must determine whether this works out unfairly for American companies.
The US government has launched an official investigation into the cost of drugs from Germany.
Coverage Details
Bias Distribution
- 47% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
